Answers are grounded in this paper and cite their sources.
Primary endpoint treatment-change-free survival (TCFS), defined as time from randomization to death or initiation of a new disease-modifying treatment in the phase 2 DELTA trial. AML, acute myeloid leukemia; EPAG, eltrombopag; HMA, hypomethylating agents; IC, intensive chemotherapy.
No takes yet. Share an insight, caveat, or question.
Sockel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: